{"schema_version":"secwatch.filing_event.v1","accession":"0001740797-25-000047","form_type":"8-K","ticker":"AVAI","cik":"0001740797","company_name":"AVAI BIO, INC.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.852238+00:00","generated_at":"2026-05-17T06:16:16.166309+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avant Technologies enters joint venture with Austrianova to form Klothonova for Klotho-based therapies","bullets":["AVAI and Austrianova form Klothonova Inc., a 50/50 joint venture to develop treatments for Alzheimer's, heart disease, cancer, kidney disease, and longevity.","AVAI will fund Klothonova's operations for 18 months up to $1.5M in exchange for 1.5M shares (50% ownership).","Austrianova contributes its proprietary cell encapsulation technology and IP as an exclusive license to Klothonova.","Potential additional $8.5M loan from AVAI for clinical development; if AVAI declines, Austrianova can pursue development outside Klothonova.","Kenn Kerr named CEO; Walter H. Günzburg, Ph.D., appointed Chairman of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001740797-25-000047","json":"https://secwatch.observer/filing/0001740797-25-000047.json","markdown":"https://secwatch.observer/filing/0001740797-25-000047.md","text":"https://secwatch.observer/filing/0001740797-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/0001740797-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/form8_avai.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:16:16.166309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}